Prostaglandin F2-alpha receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Prostaglandin F2-alpha receptor shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P43088. Start with glaucoma, then reuse UniProt P43088 as the stable protein anchor across project notes and exports.
Start with glaucoma, then reuse UniProt P43088 as the stable protein anchor across project notes and exports.
Prostaglandin F2-alpha receptor shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.
Start review with glaucoma because it currently carries approved-linked support. Linked drugs include BIMATOPROST, LATANOPROST, LATANOPROSTENE BUNOD, TAFLUPROST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProstaglandin F2-alpha receptor
Review this target as Prostaglandin F2-alpha receptor, mapped to UniProt P43088. Sequence length is 359 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostaglandin F2-alpha receptor as ChEMBL target CHEMBL1987, mapped to UniProt P43088. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Prostaglandin F2-alpha receptor is the right protein anchor across sources, using UniProt P43088 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why glaucoma is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Prostaglandin F2-alpha receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P43088 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Prostaglandin F2-alpha receptor |
| UniProt Accession | P43088 |
| Component Type | Protein |
| Sequence Length | 359 aa |
Prostaglandin F2-alpha receptor
Review this target as Prostaglandin F2-alpha receptor, mapped to UniProt P43088. Sequence length is 359 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Prostaglandin F2-alpha receptor shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block.
Start review with glaucoma because it currently carries approved-linked support. Linked drugs include BIMATOPROST, LATANOPROST, LATANOPROSTENE BUNOD, TAFLUPROST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4752237 | 9.28 | IC50 | 0.53 | Preclinical |
| CHEMBL4749822 | 9.1 | IC50 | 0.79 | Preclinical |
| CHEMBL6015710 | 9.02 | IC50 | 0.96 | Preclinical |
| CHEMBL3975522 | 9.0 | Ki | 1.0 | Clinical |
| CHEMBL2220404 | 9.0 | IC50 | 1.0 | Clinical |
| CHEMBL36041 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL4749767 | 8.96 | IC50 | 1.1 | Preclinical |
| CHEMBL5742825 | 8.92 | IC50 | 1.2 | Preclinical |
| CHEMBL5939339 | 8.8 | IC50 | 1.6 | Preclinical |
| CHEMBL5757389 | 8.77 | IC50 | 1.7 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 53 | 43 | 5.9 |
| cell-based format | 22 | 407 | 7.2 |
| assay format | 1 | 4 | 6.1 |
| tissue-based format | 1 | 1 | 7.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 17 | 81 | 7.2 |
| assay format | 10 | 10 | 6.2 |